Orforglipon is a once daily oral non-peptide, GLP-1 receptor agonist for weight management, and treatment of type two diabetes.
It is a potent potential agonist of the GLP-1 receptor and has a greater effect on cyclic AMP, signaling then on beta arrestin recruitment, a pharmacologic profile that may offer lower receptive desensitization than full GLP-1receptor agonists.
In adults with early type two diabetes, orforglipron significantly reduces glycated hemoglobin level over period of 40 weeks
Similar toxicity profile than injectable GLP-1 receptor agonists.
It has a half-life of of 29 to 49 hours, supporting once daily oral administration.
Views: 41